Forge Biologics Underscores Patient-Centric Focus in Rare Disease Efforts

According to a recent LinkedIn post from Forge Biologics, the company is emphasizing its focus on patients and communities in the run‑up to Rare Disease Day 2026. The post highlights partnerships with innovators, industry leaders, and patient families, and references an internal initiative called “Voices of Hope” aimed at keeping patient impact central to its work.

The post suggests an ongoing strategic emphasis on the rare disease segment, which may signal continued investment in gene therapy platforms and patient‑centric programs. For investors, this positioning could support Forge Biologics’ differentiation in a competitive cell and gene therapy market, potentially strengthening its reputation with partners, regulators, and advocacy groups over the long term.